Sarepta Therapeutics stated Monday night it can pause all shipments of Elevidys, its gene remedy for Duchenne muscular dystrophy, following a request by the Meals and Drug Administration.
It’s a shocking reversal by Sarepta. The corporate had initially rejected the company’s request, which was issued Friday.
Shipments will halt by shut of enterprise Tuesday night, the corporate stated.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
